Precision Medicines’ Impact on Orphan Drug Designation
Open Access
- 11 July 2019
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 12 (6) , 633-640
Abstract
The incentives provided under the Orphan Drug Act (ODA) have been credited for catalyzing the marketing approval of drugs for the treatment of rare diseases by the US Food and Drug Administration. Orphan drug designation, the granting of special status to drugs or biologics (“drugs”) for the treatment of rare diseases, one of the ODA's key incentive programs, has seen major increases in volume over recent years. The new era of precision medicine and the development of therapies directed toward smaller “orphan” subsets of common diseases have been suggested as being a major driver. We evaluated the basis for orphan drug designations and orphan subsets in relation to the impact of precision medicines. We found that the increasing numbers of orphan drug designation determinations were not driven by precision medicines separating common diseases into orphan subsets and that orphan subsets overall also represented a relatively small proportion of designations.Keywords
This publication has 12 references indexed in Scilit:
- Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other MedicinesHealth Affairs, 2018
- What Is the Purpose of the Orphan Drug Act?PLOS Medicine, 2017
- History of Orphan Drug Regulation—United States and BeyondClinical Pharmacology & Therapeutics, 2016
- A clinical pharmacology-regulatory perspective on the approval of drugs for rare diseasesClinical Pharmacology & Therapeutics, 2016
- Challenges and Hurdles to Business as Usual in Drug Development for Treatment of Rare DiseasesClinical Pharmacology & Therapeutics, 2016
- The Orphan Drug ActAmerican Journal of Clinical Oncology, 2016
- Trends In Orphan New Molecular Entities, 1983–2014: Half Were First In Class, And Rare Cancers Were The Most Frequent TargetHealth Affairs, 2016
- A New Initiative on Precision MedicineNew England Journal of Medicine, 2015
- The Future of Orphan Drug DevelopmentClinical Pharmacology & Therapeutics, 2012
- Rare diseases and orphan drugsNature Reviews Drug Discovery, 2012